Related Experiment Video
Updated: Jul 6, 2026

Development and Application of Rapamycin-regulated Tyrosine Phosphatases
Published on: September 6, 2024
Solution structure of the Legionella pneumophila Mip-rapamycin complex
Andreas Ceymann1, Martin Horstmann, Philipp Ehses
1Department of Experimental Physics 5, University of Würzburg, Würzburg, Germany. asceyman@physik.uni-wuerzburg.de
Background:
Legionella pneumphila is the causative agent of Legionnaires' disease. A major virulence factor of the pathogen is the homodimeric surface protein Mip. It shows peptidyl-prolyl cis/trans isomerase activty and is a receptor of FK506 and rapamycin, which both inhibit its enzymatic function. Insight into the binding process may be used for the design of novel Mip inhibitors as potential drugs against Legionnaires' disease.
Results:
We have solved the solution structure of free Mip77-213 and the Mip77-213-rapamycin complex by NMR spectroscopy. Mip77-213 showed the typical FKBP-fold and only minor rearrangements upon binding of rapamycin. Apart from the configuration of a flexible hairpin loop, which is partly stabilized upon binding, the solution structure confirms the crystal structure. Comparisons to the structures of free FKBP12 and the FKBP12-rapamycin complex suggested an identical binding mode for both proteins.
Conclusion:
The structural similarity of the Mip-rapamycin and FKBP12-rapamycin complexes suggests that FKBP12 ligands may be promising starting points for the design of novel Mip inhibitors. The search for a novel drug against Legionnaires' disease may therefore benefit from the large variety of known FKBP12 inhibitors.
Insights
Researchers elucidated the structure of the Mip protein from Legionella pneumophila and its complex with rapamycin. This structural insight aids in developing new drugs to combat Legionnaires
Area of Science:
- Structural biology
- Biochemistry
- Microbiology
Background:
- Legionella pneumophila causes Legionnaires' disease.
- The Mip protein is a key virulence factor with peptidyl-prolyl cis/trans isomerase activity.
- Mip binds FK506 and rapamycin, which inhibit its function.
Purpose of the Study:
- To determine the solution structure of Mip77-213 and its complex with rapamycin.
- To understand the binding mechanism of rapamycin to Mip.
- To inform the design of novel Mip inhibitors for treating Legionnaires' disease.
Main Methods:
- Nuclear Magnetic Resonance (NMR) spectroscopy was used to solve the solution structure.
- Comparison with existing FKBP12-rapamycin complex structures.
Main Results:
- The solution structure of Mip77-213 and its rapamycin complex were determined.
- Mip exhibits a typical FKBP-fold with minor rearrangements upon rapamycin binding.
- The binding mode of rapamycin to Mip is similar to that observed in FKBP12.
Conclusions:
- Structural similarity between Mip-rapamycin and FKBP12-rapamycin complexes suggests FKBP12 ligands as starting points for Mip inhibitor design.
- Known FKBP12 inhibitors can guide the development of new drugs against Legionnaires' disease.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order to...
Formation of Lipopolysaccharides
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...

